Crinetics CFO sells 6,713 shares for tax withholding

Crinetics Pharmaceuticals Chief Financial Officer Tobin Schilke reported an automatic sale of common stock tied to tax withholding.

Rhea-AI Filing Summary

Crinetics Pharmaceuticals Chief Financial Officer Tobin Schilke reported an automatic sale of common stock tied to tax withholding. On the transaction date, 6,713 shares of common stock were sold in open-market transactions to cover his tax withholding obligation upon the vesting of restricted stock units granted on March 10, 2025.

The shares were sold pursuant to a pre-arranged Rule 10b5-1 trading plan, with a volume-weighted average price of $39.67 per share and a sale price range of $39.67 to $39.74 per share. After this tax-related sale, he directly held 78,121 shares of Crinetics common stock.

Insider Trade Summary

Net Seller: 6,713 shares

Net Sell 1 txn

Insider Schilke Tobin

Role Chief Financial Officer

Sold 6,713 shs ($266K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,713	$39.67	$266K

Holdings After Transaction: Common Stock — 78,121 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 10, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
2. F2. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Crinetics (CRNX) disclose for its CFO?

Crinetics reported its Chief Financial Officer, Tobin Schilke, sold 6,713 shares of common stock. The sale was executed to cover tax withholding obligations from vesting restricted stock units under a Rule 10b5-1 trading plan, rather than a discretionary open-market sale.

At what price did the Crinetics (CRNX) CFO sell his shares?

The CFO’s shares were sold at a volume-weighted average price of $39.67 per share. The individual trade prices on the transaction date ranged from $39.67 to $39.74 per share, according to the detailed pricing disclosure associated with the transaction.

Why did the Crinetics (CRNX) CFO sell 6,713 shares of stock?

The CFO sold 6,713 shares solely to cover his tax withholding obligation when previously granted restricted stock units vested. This tax-related disposition was carried out by a broker under instructions in a pre-established Rule 10b5-1 trading plan.

How many Crinetics (CRNX) shares does the CFO hold after this transaction?

Following the tax-related sale of 6,713 shares, the Crinetics Chief Financial Officer directly holds 78,121 shares of the company’s common stock. This post-transaction ownership amount is explicitly stated in the Form 4 disclosure for the reported trade.

Was the Crinetics (CRNX) CFO sale part of a Rule 10b5-1 trading plan?

Yes. The Form 4 notes the disposition was effected by a broker under instructions in a Rule 10b5-1 trading plan adopted by the CFO. Such plans pre-schedule trades, helping separate routine transactions from discretionary timing decisions by insiders.

What triggered the tax withholding sale reported by Crinetics (CRNX)?

The sale was triggered by the vesting of restricted stock units granted to the CFO on March 10, 2025. When these RSUs vested, shares were sold to satisfy his associated tax withholding obligation, as described in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 05:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schilke Tobin

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		6,713	D	$39.67(2)	78,121	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 10, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

Remarks:

	/s/ Tobin Schilke	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.